CN1805748B - 作为raf激酶抑制剂的2-氨基嘧啶衍生物 - Google Patents

作为raf激酶抑制剂的2-氨基嘧啶衍生物 Download PDF

Info

Publication number
CN1805748B
CN1805748B CN2004800163287A CN200480016328A CN1805748B CN 1805748 B CN1805748 B CN 1805748B CN 2004800163287 A CN2004800163287 A CN 2004800163287A CN 200480016328 A CN200480016328 A CN 200480016328A CN 1805748 B CN1805748 B CN 1805748B
Authority
CN
China
Prior art keywords
halogen
alkyl
compound
alkoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800163287A
Other languages
English (en)
Chinese (zh)
Other versions
CN1805748A (zh
Inventor
D·B·巴特
T·M·拉姆齐
M·L·萨比奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1805748A publication Critical patent/CN1805748A/zh
Application granted granted Critical
Publication of CN1805748B publication Critical patent/CN1805748B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2004800163287A 2003-06-13 2004-06-11 作为raf激酶抑制剂的2-氨基嘧啶衍生物 Expired - Fee Related CN1805748B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47870903P 2003-06-13 2003-06-13
US60/478,709 2003-06-13
PCT/EP2004/006317 WO2004110452A1 (en) 2003-06-13 2004-06-11 2-aminopyrimidine derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
CN1805748A CN1805748A (zh) 2006-07-19
CN1805748B true CN1805748B (zh) 2010-05-26

Family

ID=33551850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800163287A Expired - Fee Related CN1805748B (zh) 2003-06-13 2004-06-11 作为raf激酶抑制剂的2-氨基嘧啶衍生物

Country Status (14)

Country Link
US (1) US20060293340A1 (enExample)
EP (1) EP1635835B1 (enExample)
JP (1) JP2006527230A (enExample)
CN (1) CN1805748B (enExample)
AT (1) ATE454152T1 (enExample)
AU (1) AU2004246800B2 (enExample)
BR (1) BRPI0411365A (enExample)
CA (1) CA2529090A1 (enExample)
DE (1) DE602004024988D1 (enExample)
ES (1) ES2338557T3 (enExample)
MX (1) MXPA05013349A (enExample)
PL (1) PL1635835T3 (enExample)
PT (1) PT1635835E (enExample)
WO (1) WO2004110452A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
UA94570C2 (en) * 2004-09-09 2011-05-25 Натко Фарма Лимитед Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
CN1939910A (zh) 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
MX2007011866A (es) * 2005-02-25 2007-10-10 Novartis Ag Combinacion farmaceutica de inhibidores de bcr-abl y raf.
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EA200870217A1 (ru) * 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
ES2496592T3 (es) 2006-11-16 2014-09-19 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Proceso para la preparación de Imatinib y compuestos intermedios del mismo
JP5160637B2 (ja) * 2007-05-04 2013-03-13 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼインヒビターとしての化合物および組成物
US9062023B2 (en) 2007-06-07 2015-06-23 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
JP5511680B2 (ja) 2007-12-19 2014-06-04 キャンサー・リサーチ・テクノロジー・リミテッド ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
CA2716951A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
SG185664A1 (en) * 2010-05-11 2012-12-28 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20130116291A (ko) * 2010-11-19 2013-10-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Braf 억제제를 이용한 치료 방법
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP6795518B2 (ja) * 2015-04-23 2020-12-02 インヒビカーセ セラピューティクス，インコーポレーテッド キナーゼを阻害する組成物及び方法
CN108586439A (zh) * 2018-06-03 2018-09-28 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108864060A (zh) * 2018-06-03 2018-11-23 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108610336A (zh) * 2018-06-03 2018-10-02 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN118891251A (zh) * 2022-02-03 2024-11-01 奈可萨斯医药有限公司 芳基烃受体激动剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180631B1 (en) * 1997-10-06 2001-01-30 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
WO2002022597A1 (en) * 2000-09-13 2002-03-21 Novartis Ag N-phenyl-2-pyrimidine-amine derivatives
WO2002093164A2 (en) * 2001-05-16 2002-11-21 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases
WO2003022833A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridylfurans and pyrroles as raf kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2003070173A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
JP4552650B2 (ja) * 2002-06-28 2010-09-29 日本新薬株式会社 アミド誘導体及び医薬
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180631B1 (en) * 1997-10-06 2001-01-30 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
WO2002022597A1 (en) * 2000-09-13 2002-03-21 Novartis Ag N-phenyl-2-pyrimidine-amine derivatives
WO2002093164A2 (en) * 2001-05-16 2002-11-21 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases
WO2003022833A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridylfurans and pyrroles as raf kinase inhibitors

Also Published As

Publication number Publication date
BRPI0411365A (pt) 2006-07-25
AU2004246800A1 (en) 2004-12-23
PT1635835E (pt) 2010-03-17
AU2004246800B2 (en) 2008-12-04
PL1635835T3 (pl) 2010-06-30
DE602004024988D1 (de) 2010-02-25
ATE454152T1 (de) 2010-01-15
CN1805748A (zh) 2006-07-19
WO2004110452A1 (en) 2004-12-23
EP1635835B1 (en) 2010-01-06
ES2338557T3 (es) 2010-05-10
JP2006527230A (ja) 2006-11-30
CA2529090A1 (en) 2004-12-23
US20060293340A1 (en) 2006-12-28
MXPA05013349A (es) 2006-03-09
EP1635835A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
CN1805748B (zh) 作为raf激酶抑制剂的2-氨基嘧啶衍生物
AU2012208388B2 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
US8288540B2 (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US7074799B2 (en) Substituted quinazolin-4-ylamine analogues
EP2190825B1 (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
CN104024233A (zh) 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物
WO2014165232A1 (en) Compounds for treatment of cancer
US20070027150A1 (en) 2-Amino-quinazolin-5-ones
CN107793417B (zh) 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
JP2010524885A (ja) がん治療剤としてのナフタレンカルボン酸アミドのエーテル
CN114555597A (zh) 异柠檬酸脱氢酶（idh）抑制剂
WO2024240108A1 (zh) 一种芳基脲类parp1抑制剂、其制备方法及用途
AU2003205217A1 (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100526

Termination date: 20110611